| scholarly article | Q13442814 |
| P50 | author | Hagop Kantarjian | Q60394812 |
| Farhad Ravandi | Q40614280 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| P2093 | author name string | Yiming Chen | |
| Haijun Wang | |||
| P2860 | cites work | Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid) | Q67915608 |
| Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program | Q69833744 | ||
| Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity | Q81623816 | ||
| Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy | Q26825852 | ||
| United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia | Q28216403 | ||
| All-trans-retinoic acid in acute promyelocytic leukemia | Q28250406 | ||
| Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia | Q28291815 | ||
| Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis | Q28295879 | ||
| Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients | Q28376006 | ||
| Differentiation therapy of leukemia: 3 decades of development | Q33409795 | ||
| Acute promyelocytic leukemia. M.D. Anderson Hospital experience | Q33452068 | ||
| Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data | Q33636371 | ||
| Introduction: the history of arsenic trioxide in cancer therapy. | Q33944990 | ||
| All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. | Q34155766 | ||
| Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. | Q34310859 | ||
| Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide | Q34478428 | ||
| Acute promyelocytic leukemia: evolving therapeutic strategies | Q34503964 | ||
| Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia | Q34563645 | ||
| Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. | Q34585850 | ||
| Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials | Q34608688 | ||
| Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells | Q34739775 | ||
| Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients | Q34739789 | ||
| Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation | Q35757247 | ||
| Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin | Q36938551 | ||
| Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia | Q37117735 | ||
| Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid | Q37216174 | ||
| Acute promyelocytic leukaemia: novel insights into the mechanisms of cure | Q37802188 | ||
| Modern approaches to treating acute promyelocytic leukemia | Q37827280 | ||
| Revisiting the differentiation paradigm in acute promyelocytic leukemia | Q37858862 | ||
| Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. | Q37923444 | ||
| Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. | Q38463036 | ||
| Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells | Q40163168 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide | Q40618562 | ||
| All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study | Q43638984 | ||
| Acute promyelocytic leukemia--weapons of mass differentiation. | Q51796993 | ||
| Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. | Q54367099 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute promyelocytic leukemia | Q612108 | ||
| P304 | page(s) | 5811-5818 | |
| P577 | publication date | 2012-06-15 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. | |
| P478 | volume | 118 |
| Q44333428 | Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study |
| Q39279196 | Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. |
| Q30240249 | Acute promyelocytic leukemia: preventing early complications and late toxicities. |
| Q36253767 | Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California |
| Q64119389 | Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia |
| Q57120135 | Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment |
| Q40413191 | Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab |
| Q53486790 | Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. |
| Q38108471 | Management of elderly patients with acute promyelocytic leukemia: progress and problems |
| Q36941941 | New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach |
| Q36508333 | Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group |
| Q38661486 | Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. |
| Q64092490 | Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia |
| Q41662169 | Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. |
| Q57020375 | Toward the potential cure of leukemias in the next decade |
| Q92438473 | Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia |
Search more.